FTC Says USAP Deal Would Restore Texas Anesthesia Competition

The proposed settlement would resolve federal allegations that a decade-long roll-up let one anesthesia provider demand higher rates in Texas.

WASHINGTON, D.C. - The Federal Trade Commission said it reached an agreement in principle with U.S. Anesthesia Partners Inc. to settle federal litigation over Texas anesthesia markets, a case the agency brought after alleging that USAP used acquisitions and contracting tactics to build market power and raise prices.

The FTC said the preliminary deal would restore competition for anesthesia services in Texas if it is fully executed. The company said the final settlement would be made without any admission of fault and that resolving the case would avoid disruption for patients, clinicians, and hospital partners.

The stakes reach beyond one company. The case tests how federal antitrust enforcers treat health care roll-ups, where a provider can acquire local competitors, gain bargaining power with insurers and hospitals, and shift higher medical costs through the commercial insurance system.

The Story So Far

The FTC sued USAP in 2023 in the U.S. District Court for the Southern District of Texas, case No. 4:23-cv-03560. The agency's complaint alleged that USAP bought up large anesthesia practices across Texas and used the acquisitions to create a dominant provider with power to demand higher rates.

According to the FTC's 2023 enforcement announcement, the agency alleged a three-part strategy: roll-up acquisitions of anesthesia practices, price-setting arrangements with remaining independent practices, and a market allocation deal that kept a significant competitor out of USAP territory. The FTC said the strategy affected Texas markets including Houston and Dallas.

The complaint alleged that USAP acquired more than a dozen anesthesiology practices in Texas after its creation. The FTC said that after each acquisition, USAP raised the acquired group's rates to USAP's higher rates, which the agency described as a substantial markup for the same doctors as before.

The FTC also alleged that the conduct cost Texans tens of millions of dollars more each year for anesthesia services than before USAP was created. USAP has disputed the allegations and said it operated responsibly in Texas.

What's Happening Now

The FTC said on April 23 that it had reached an agreement in principle with USAP to settle the litigation. The agency said the Commission voted 2 to 0 to authorize staff to agree to the preliminary settlement.

The terms are not public yet. The FTC said the substance of the agreement is confidential for now so USAP can conduct negotiations needed to execute the settlement. The agency said any final order will require another Commission vote and approval by the district court.

That makes the deal a path forward, not a completed remedy. The FTC said it would return to district court to litigate the challenged acquisitions if USAP does not fully execute the settlement.

USAP framed the agreement as a practical resolution. In its company release, The company said the settlement remains subject to several conditions and would be made without any admission of fault by the company.

The Conservative View

The conservative case for the FTC action starts with competition and medical prices. The FTC's complaint alleged that USAP's acquisitions reduced local alternatives in anesthesia services, which the agency said gave the company power to negotiate higher rates.

That argument fits a market-focused antitrust view: when local competitors disappear, hospitals and insurers may have fewer substitutes, and a provider can use scarcity to raise prices without improving the underlying service. The FTC's 2023 announcement said acquired practices were moved to higher USAP rates after deals closed.

The conservative caution is that antitrust enforcement should not become hostility to scale itself. Larger medical groups can argue that size helps with staffing, compliance, scheduling, and subspecialty coverage. The company said it serves more than 700 facilities, handles more than 2 million cases annually, and works with more than 4,500 clinicians across anesthesiology roles and subspecialties.

The Progressive View

The progressive case emphasizes private equity-style consolidation in health care and the pass-through of medical costs to patients and workers. The FTC's original case named Welsh, Carson, Anderson & Stowe along with USAP, and the agency alleged that a roll-up strategy consolidated anesthesia practices in Texas.

From that perspective, the alleged harm is not just a higher bill in one operating room. Employer plans, insurers, and patients can absorb higher negotiated rates through premiums, cost sharing, or hospital contract pressure. The FTC said Texans paid tens of millions of dollars more each year because of the alleged conduct.

Progressives also tend to argue that health care markets need special attention because patients rarely choose an anesthesiology provider in the same way they shop for ordinary services. The FTC's theory focuses on the bargaining layer before care happens: which anesthesia group contracts with hospitals and insurers, and what rates those contracts permit.

Other Perspectives

USAP's position is that settlement avoids uncertainty without conceding wrongdoing. Scott Holliday, DO, MBA, USAP physician and board chairman, said the company believes it has strong defenses and operated responsibly in Texas, but that resolving the case is in the best interests of patients, clinicians, and hospital partnerships.

A libertarian view cuts in two directions. One side favors strict enforcement against arrangements that block entry or allocate markets, because those tactics can protect incumbents from competition. Another side worries that vague settlement terms and prolonged federal litigation can chill lawful acquisitions that may improve efficiency.

Texas employers and privately insured patients have the most direct economic exposure under the FTC's theory. The agency did not allege a general health inflation story. It alleged a narrower mechanism: local consolidation in a specialized physician services market, followed by higher negotiated rates charged through the health care payment chain.

Economic Implications

The economic mechanism is bargaining power. According to the FTC, USAP's acquisitions removed independent anesthesia groups from local markets, which reduced alternatives for insurers and hospital partners. If an insurer has fewer anesthesia groups available for a hospital network, the remaining provider can demand higher reimbursement rates.

Those rates do not stop at the negotiating table. Commercial insurers can pass higher provider payments into premiums, employers can absorb or share those costs with workers, and patients can face higher out-of-pocket bills depending on plan design. The FTC alleged the conduct cost Texans tens of millions of dollars more each year for anesthesia services.

For the broader U.S. economy, the case matters because health care is a major household and employer cost center. The FTC's theory shows how consolidation in a narrow professional services market can affect prices even when patients never see the business negotiation that sets the bill. That is the America First angle: local medical market structure can become a direct cost issue for American workers and employers.

The final settlement terms will determine the actual business impact. If the order requires divestitures, contract limits, or restrictions on price-setting arrangements, the remedy could alter how anesthesia groups structure expansion in Texas. If the relief is narrower, the case may still serve as a warning to health care buyers and private equity sponsors that roll-up strategies can draw federal scrutiny when pricing power follows.

By the Numbers

• 2 to 0: The FTC vote authorizing staff to agree to the preliminary settlement, according to the agency.
• More than a dozen: The number of Texas anesthesiology practices the FTC said USAP acquired after its creation.
• Tens of millions of dollars: The annual additional cost to Texans alleged by the FTC in its 2023 enforcement announcement.
• More than 700: Facilities where The company said its clinicians provide anesthesia care nationwide.
• More than 2 million: Annual cases The company said its anesthesia teams handle.
• More than 4,500: USAP clinicians cited in the company's release.

What People Are Saying

"The Federal Trade Commission has reached an agreement in principle with U.S. Anesthesia Partners Inc. (USAP) to settle the litigation and restore competition for anesthesia services in Texas," the FTC said in its April 23 announcement.

"The substance of the agreement is confidential at present to facilitate the negotiations USAP must undertake to execute the settlement," the FTC said.

"But the terms of the settlement, if fully executed, will restore a competitive market structure and will be consistent with longstanding FTC settlement best practices," the FTC said.

"If USAP fails fully to execute the settlement, the FTC will return to district court to litigate these unlawful acquisitions," the FTC said.

"The settlement is subject to several conditions, and any final settlement will be made without an admission of fault by USAP," the company release said.

"USAP believes it has strong defenses to the FTC's allegations and has operated responsibly in the state of Texas," Holliday said in the company release, adding that avoiding disruption, litigation cost, time commitment, and uncertainty is in the best interests of patients, clinicians, and hospital partnerships.

The Big Picture

The settlement is still unfinished. The FTC said a final order needs another Commission vote and district court approval, and the company said the agreement remains subject to conditions.

The next test is whether the final terms show a structural remedy, conduct restrictions, or a mix of both. For health care businesses, the result will help define how far federal antitrust enforcers are willing to go when they say a roll-up strategy converted local medical practices into pricing power.

For Texas patients, employers, insurers, and hospitals, the practical question is whether the remedy changes the negotiating alternatives available in anesthesia markets. The case began as an antitrust fight, but its final effect will be measured in the prices paid for medical care.